Logo

Novartis to Acquire Cadent Therapeutics for ~$770M

Share this

M&A

Novartis to Acquire Cadent Therapeutics for ~$770M

Shots:

  • Novartis to acquire all outstanding shares of Cadent for a total value of ~$770M. Cadent to receive $210M up front and is eligible for ~$560M as milestones. The transaction is expected to be close in Q1’21
  • Novartis gains full rights to Cadent’s NMDAr program which consist of two clinical programs: CAD-9303 and MIJ-821- an NMDAr negative allosteric modulator that was licensed to Novartis in 2015
  • Additionally- Novartis gains Cadent’s pre-clinical programs and clinical stage (CAD-1883) movement disorder program

­ Ref: Novartis | Image: Novartis

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions